Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan-Feb;39(1):12-20.
doi: 10.1016/j.hrtlng.2009.04.001. Epub 2009 Sep 30.

Patient perception of symptoms and quality of life following ablation in patients with supraventricular tachycardia

Kathryn A Wood  1 , Anita L Stewart, Barbara J Drew, Melvin M Scheinman, Erika S Froëlicher
Affiliations

Patient perception of symptoms and quality of life following ablation in patients with supraventricular tachycardia

Kathryn A Wood et al. Heart Lung. 2010 Jan-Feb.

Abstract

Objectives: It remains unclear which symptom experiences and aspects of quality of life (QOL) change after ablation in patients with supraventricular tachycardia (SVT). To determine how patient perceptions of symptoms and QOL change after ablation, we used a single group pretest-posttest design.

Methods: Patients with SVT (n=52; mean age 41+/-17 years; 65% female) completed generic and disease-specific measures at baseline and 1 month after ablation.

Results: Significant improvement after ablation was noted on virtually all measures (P <.05). Patients reported decreases from baseline regarding frequency and duration of episodes, number of symptoms, and impact of SVT on routine activities. All symptoms decreased in prevalence; however, no symptoms were completely eliminated at 1-month follow-up. Women, more so than men, reported larger changes in symptom and QOL scores after ablation.

Conclusions: Despite the small sample, statistically significant improvement was found after ablation in a variety of patients with different symptoms and QOL indices.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow chart of recruitment for study
SVT: supraventricular tachycardia, EP: electrophysiology. Of the initial exclusions, 281 were for non-SVT primary diagnoses as follows: cardioversions (35); pacemakers (94); implantable cardioverter defibrillator (71); ventricular tachycardia (73); long QT syndrome (8). Of the secondary exclusions, 125 SVT patients were excluded due to: severe co-morbid conditions (7); ineligible arrhythmia diagnoses for study, such as atrial fibrillation (49), atrial flutter (30), inappropriate sinus tachycardia (6); non-inducibility at time of electrophysiology testing or unsuccessful ablation (11); history of earlier ablation (10); age ≤ 12 years (4); or non-English speaking (8).
See this image and copyright information in PMC

References

    1. Cohn J. Efficacy and safety in clinical trials in cardiovascular disease. J Am Coll Cardiol. 2006;48:430–433. - PubMed
    1. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for management of supraventricular arrhythmias: Executive summary. Circulation. 2003;108:1871–1909. - PubMed
    1. Morady F. Catheter ablation of supraventricular arrhythmias: State of the art. Pacing Clin Electrophysiol. 2004;27:125–142. - PubMed
    1. Josephson ME, Wellens H. Differential diagnosis of supraventricular tachycardia. Cardiol Clin. 1990;8:411–442. - PubMed
    1. Wood K. Mechanisms and clinical manifestations of supraventricular tachycardias. Prog Cardiovasc Nurs. 1995;10(2):3–14. - PubMed

Publication types